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Abstract
Absolute quantification of protein expression and post-translational modifications by mass 
spectrometry has been challenging due to a variety of factors, including the potentially large 
dynamic range of phosphorylation response. To address these issues, we have developed 
MARQUIS — Multiplex Absolute Regressed Quantification with Internal Standards — a novel 
mass spectrometry-based approach using a combination of isobaric tags and heavy-labeled 
standard peptides to construct internal standard curves for peptides derived from key nodes in 
signal transduction networks. We applied MARQUIS to quantify phosphorylation dynamics 
within the EGFR network at multiple time points following stimulation with several ligands, 
enabling a quantitative comparison of EGFR phosphorylation sites and demonstrating that 
receptor phosphorylation is qualitatively similar but quantitatively distinct for each EGFR ligand 
tested. MARQUIS was also applied to quantify the effect of EGFR kinase inhibition on 
glioblastoma patient derived xenografts. MARQUIS is a versatile method, broadly applicable and 
extendable to multiple mass spectrometric platforms.
Introduction
Innovations over the past decade in methodology and instrumentation have greatly increased 
the capability of mass spectrometry to identify a significant fraction of the proteome, 
including thousands of post-translational modifications (PTMs)1. Through the use of 
quantitative strategies, including label-free proteomics, metabolic stable isotope labeling, 
*CORRESPONDING AUTHOR: Forest M. White (fwhite@mit.edu). 
Author contributions:
T.G.C., Y.Z., and D.J.M. performed experiments and analyzed data. T.G.C., Y.Z., D.J.M., J.S., and F.M.W. designed the experiments 
and wrote the manuscript.
Competing financial interests:
The authors declare no competing financial interests
NIH Public Access
Author Manuscript
Nat Commun. Author manuscript; available in PMC 2015 July 12.
Published in final edited form as:













and chemical stable isotope labeling, it is possible to analyze two or more biological samples 
and generate relative quantification data detailing differences in protein expression or 
modification across different cellular conditions2,3. Multiplex labeling has effectively 
improved the throughput of the approach, enabling the comparison of multiple different 
biological samples in a single analysis, with quantification typically determined relative to a 
basal condition or pooled standard. Multiplexed relative quantification has been useful for 
elucidating temporal dynamics of phosphorylation signaling following growth factor 
stimulation, with changes in protein PTM levels in stimulated vs. non-stimulated conditions 
highlighting pathways involved in signal processing and cellular response4. When combined 
with bioinformatic algorithms, such as clustering, relative quantification of PTM level has 
enabled researchers to predict the function of poorly characterized phosphorylation sites5. 
Through quantification of downstream biological response and statistical analysis, key sites 
have been identified as regulators of observed cellular behavior, providing further functional 
and phenotypic association for novel phosphorylation sites6.
Despite the ability to generate biological insight with a combination of relative 
quantification of phosphorylation dynamics and statistical modeling or bioinformatics, 
additional information is encoded in the absolute levels of site-specific phosphorylation. For 
instance, relative fold change of a signal carries limited information about the network’s 
basal state or response to stimuli, as a two-fold change from a high basal state (e.g. 30% to 
60% activation) can lead to a very different biological response from a two-fold change 
from a very low basal state (e.g. 1% to 2% activation). Absolute quantitation also enables 
comparison between multiple phosphorylation sites on a given protein under different 
conditions. Since each phosphorylation site might recruit adaptor proteins associated with 
particular signaling pathways, absolute quantification of phosphorylation can provide 
critical data relating receptor stimulation and pathway activation.
Absolute quantification of phosphorylation incorporation has historically been performed by 
using radiolabeled ATP and tryptic digestion followed by 2D thin-layer chromatography; 
however it is difficult to identify the specific phosphorylation sites corresponding to each 
peptide, the method is limited to single protein analysis, and the phosphorylation reaction 
must occur in vitro (in cell lysates) or in cells whose membranes have been disrupted. In 
considering more high-throughput techniques, absolute quantification data is not typically 
available from standard mass spectrometry, western-blot, or reverse-phase protein array 
experiments, as the calibration curve is unique to each phosphorylated peptide due to 
different response profiles (e.g. ionization potential or antibody binding affinity). Therefore 
multiple methods for estimating absolute quantification have been established. Among 
these, one of the most common MS-based methods is isotope dilution, or AQUA, in which a 
synthetic isotope-encoded peptide is added to the sample pre-analysis, and quantification is 
based on the relative peak heights or area under the chromatographic elution curve for the 
endogenous and synthetic peptide standard7. Although this technique is fairly 
straightforward, it relies on single point calibration and may provide erroneous estimates if 
the endogenous peptides span a large dynamic range across multiple conditions, or if the 
concentrations of these peptides fall outside of the linear response range of the instrument. 
Alternate methods for absolute quantification include the generation of standard curves 
through separate analyses of standard peptides at known concentration7. Since the complex 
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background of the biological context can significantly alter the signal intensity of the 
endogenous peptide due to competition for charge in the ionization process in MS, 
comparison to a standard curve generated in a neat background can lead to significant 
estimation errors. One solution would include different concentrations of a standard peptide 
into the sample so that the standard and endogenous peptides experience the same local 
sample context, but then one is faced with the issue of differentiating the standards from the 
endogenous peptides. Ideally, one would like to combine the multiplexed capabilities of 
chemical labeling with standard curves internal to the sample, thus allowing the accurate, 
absolute quantification of given peptides across multiple biological conditions within a 
single analysis.
With these goals in mind, we have developed Multiplex Absolute Regressed Quantification 
of Internal Standards (MARQUIS), an MS-based technique to measure the absolute amount 
of modification on many post-translational sites of interest simultaneously from multiple 
samples within a single analysis. The method utilizes multiple doses of internal standards to 
bracket a broad abundance range allowing simultaneous analysis of treatment conditions 
expected to produce widely varied endogenous signal magnitudes. We applied MARQUIS 
to quantify the absolute amount of phosphorylation on several sites in the Epidermal growth 
factor receptor (EGFR) network at different time points following stimulation of EGFR with 
different ligands. Absolute quantification of phosphorylation dynamics in this system 
highlights novel wiring within the network, insight that was not previously available from 
relative quantification data. MARQUIS enables the acquisition of accurate absolute 
quantification data, is applicable across multiple instrument platforms, and is equally 
applicable to protein expression profiling and PTM quantification.
Results
Assessing the requirement for standard peptides
To assess the need for internal standards, we selected several tyrosine phosphorylation sites 
in the EGFR signaling network, generated synthetic phosphorylated peptides encompassing 
these sites, and added these peptides at defined concentrations to cell lysate of MCF10A 
cells. Quantification of the signal intensity for each peptide across multiple different 
analyses demonstrated a significant amount of run-to-run variation (three representative 
examples are presented in Figure 1), likely associated with small flow rate fluctuations 
combined with differences in temporal sampling across the chromatographic elution profile. 
To quantify this data across multiple concentrations of each peptide, we calculated the 
response ratio, the ratio between signal amplitude and peptide concentration, for 13 peptides 
in the EGFR signaling network (Supplementary Fig. 1). As the data demonstrates, for a 
given concentration, the response ratio can vary by two to three orders of magnitude. This 
variation is likely associated with differences in ionization potential of the peptides and their 
respective co-eluting species, due to competition for charge in electrospray ionization. 
Together, the broad range in peptide-specific response ratio and the technical replicate 
variation make it difficult to directly relate signal intensity and abundance, thereby 
highlighting the need for an improved method to generate accurate absolute quantification 
data.
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The MARQUIS method for absolute quantification
To quantify the absolute levels of endogenous peptides across a broad dynamic range, we 
have developed the MARQUIS (Multiplex Absolute Regressed Quantification of Internal 
Standards) method. Absolute quantification in MARQUIS is based on comparison of the 
endogenous peptides to paired heavy-isotope labeled internal standards added at specific 
concentrations into multiple biological samples (Fig. 2). Briefly, synthetic peptides 
containing a heavy-isotope labeled amino acid were generated for each phosphorylated 
peptide of interest and stock concentrations were established by amino-acid analysis (AAA). 
A standard peptide cocktail was then added to cell lysates; one concentration per lysate. 
These lysates were purified and digested prior to stable isotope labeling (iTRAQ) and 
combination. The mix of endogenous and synthetic peptides was subjected to targeted 
tandem mass spectrometry for iTRAQ quantification and peptide sequence confirmation. 
Sequence specific transitions were chosen based on previously observed fragmentation of 
the same peptides. Isobaric phospho-isoforms of the same peptide did not co-elute, enabling 
quantification of each isoform. Fragmentation of the iTRAQ-labeled synthetic, heavy-
labeled phosphopeptide produced an internal standard curve with each calibration point 
corresponding to the unique amount of synthetic peptide added to the corresponding 
biological sample. Similarly, fragmentation of the iTRAQ-labeled endogenous peptide also 
produced iTRAQ marker ions, with the intensity of each ion corresponding to the amount of 
endogenous peptide in each biological sample. Calibration of the iTRAQ marker ion 
intensities from the endogenous peptide against the standard curve provided absolute 
quantification for each biological condition. The internal standard curve establishes the 
linear dynamic range around the endogenous peptide concentration, providing an accurate 
intrinsic quality assessment of the peptide quantification.
Since synthetic peptides are added early in the processing workflow, losses are identical for 
the endogenous and synthetic peptides as both experience identical environments through all 
post-digestion stages of preparation. Moreover, since the endogenous and heavy-labeled 
peptides co-elute, the peptides experience identical chromatographic and ionization contexts, 
removing an additional potential source of quantification error.
Performance of the method
To assess the performance of the MARQUIS method, heavy-labeled synthetic 
phosphorylated peptides were generated for selected tyrosine phosphorylation sites in the 
EGFR signaling network. Synthetic peptides were added to EGF-stimulated MCF10A cell 
lysate, thereby providing a complex, biologically-relevant background for testing the 
response profile, linear dynamic range, and sensitivity of this method. MARQUIS was 
initially evaluated on a triple quadrupole instrument operating in multiple reaction 
monitoring (MRM) mode, with 10 precursor-fragment ion transitions per peptide, including 
2 sequence specific and 8 iTRAQ marker ion transitions (Supplementary Figs. 2, 3 and 
Supplementary Table 1). It is important to note that the number of phosphorylation sites able 
to be monitored with this approach is inherently limited by the number of transitions. With 
10 transitions per peptide and 2 peptides (synthetic and endogenous) per phosphorylation 
site, the total number of transitions increases rapidly as more sites in the network are 
monitored. Increasing the number of transitions translates to fewer measurements per 
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peptide across the chromatographic elution profile, leading to sub-optimal quantitative data. 
To address this issue, we also evaluated MARQUIS on an Orbitrap-based instrument 
(QExactive) using targeted tandem mass spectrometry, also known as parallel reaction 
monitoring (PRM). In this approach, a full scan, high-resolution MS spectrum is acquired 
followed by full scan, high-resolution MS/MS spectra containing both iTRAQ marker ions 
and sequence specific peptide fragmentation for each peptide (Supplementary Fig. 4). Since 
the endogenous and heavy-labeled peptides are both detected in the MS scan, quantitative 
comparison of the precursor ion intensities provides an estimate of the total amount of 
endogenous peptide present in the sample (Supplementary Table 2). The relative iTRAQ 
marker ion intensities from the MS/MS spectrum for the endogenous peptide then apportion 
this total amount across the biological samples. iTRAQ marker ion intensities from the 
MS/MS of the standard peptide serve as an important control by providing a peptide-specific 
estimate of the accuracy and linear dynamic range. For both the MRM and PRM methods, 
we selected 13 phosphorylation sites to assess the performance of MARQUIS quantification 
at different peptide concentrations (full data available in Supplementary Table 3, 
representative temporal data for two peptides are plotted in Supplementary Fig. 5). 
Representative data extracted for two standard peptides using MRM and PRM is shown in 
Figure 3. At the high end of the curve, both methods perform identically. For EGFR pY1173 
(Fig. 3a), the linear range for both MRM and PRM extends from 3000 fmol to 100 fmol; 
between 100 fmol and 3 fmol the response remains linear, but deviates from the theoretical 
response due to additional noise in the experimental measurement. For Shc pY317 (Fig. 3b) 
the PRM method performs well with a dynamic range of approximately 1000-fold (3000 
fmol to 3 fmol). The MRM method for this site did not perform as well, with suspected 
contamination on the iTRAQ-118 (10 fmol) channel boosting the recorded intensity 
significantly. This contamination does not appear to affect the iTRAQ-119 (3 fmol) or 
iTRAQ-121 (1 fmol) channels as both show measurably lower values than iTRAQ-117 (30 
fmol). Contamination may appear in the MRM method and not the PRM method due to the 
ability of the high resolution PRM method to distinguish contaminant ions from iTRAQ 
marker ions, whereas the MRM measurement detects the number of ions passing a set 
bandwidth in the third quadrupole. It is worth noting that altering the dwell time per 
transition for MRM or the ion target value and maximum fill time for the PRM method can 
affect the sensitivity of the analysis and thereby improve the linear dynamic range, but 
increasing these values comes at the expense of cycle time.
To evaluate the reproducibility of quantification using the MARQUIS method, we 
performed technical replicates of each experiment on the MRM and PRM platforms and 
plotted the concentration vs. coefficient of variation (CV) for each measurement in the data 
set (Fig. 3c). Although both methods provide high quality data (e.g. most measurements 
have CV <0.15) across the entire range, the most reproducible measurements are obtained 
above 100 fmol, with CV values <0.1. At the low end of the concentration range, some 
peptides display CV >0.5. For MRM, the early time points of ERK1 and ERK2 signals 
exhibited the highest CV, likely due to the combination of low endogenous signal coupled to 
the higher standard doses included in the corresponding channels. Inclusion of a second 
heavy-labeled amino acid residue would increase the spacing between the endogenous and 
standard peptides and thereby decrease the potential issue of isolation window 
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contamination. The highest CV’s for the PRM technique were those of the dual 
phosphorylated EGFR peptide pY1045/pY1068. This peptide has a lower response ratio 
(Supplementary Fig. 1) and elutes very late in the chromatographic program, making it more 
susceptible to contamination from background chemical noise. Overall, both techniques 
were comparable in terms of the fraction of measurements that met CV thresholds (Fig. 3d) 
at a CV of 0.20.
Isolation Width Effects
In the MARQUIS method, both the endogenous and the heavy-labeled synthetic peptides are 
iTRAQ labeled, allowing for direct comparison of iTRAQ marker ion intensities resulting 
from fragmentation of the corresponding peptides. This approach has the potential for error 
associated with contamination of the isolation window from other endogenous or synthetic 
peptides, or potentially from co-isolation of the endogenous and heavy-labeled peptides. As 
the charge state of the peptide increases, the separation, in m/z, between the endogenous and 
heavy-labeled synthetic peptide decreases, thereby increasing the likelihood of co-isolation. 
To assess the effect of the isolation width on MARQUIS quantification accuracy for the 
MRM platform, we narrowed the isolation width on the first quadrupole from 0.7m/z to 
0.1m/z. Narrowing the MS1 isolation window can decrease the level of contamination in the 
ions selected for fragmentation, but also significantly decreases the transmission efficiency. 
To determine if this trade-off was beneficial, we compared the measured signal intensities 
from all peptides from analyses run with both isolation widths (Supplementary Fig. 6). 
Minimal effects of altered isolation width were seen for the highest peptide levels, whereas 
only the 0.1m/z isolation window was able to clearly distinguish the median of the 1fmol 
standard from the median of the 10fmol standard. At the lowest peptide levels, the narrower 
isolation width was better able to isolate precursor ions, ultimately providing a larger 
dynamic range for calibration. However, for peptides with poor response ratios, the losses 
associated with the narrower isolation width ultimately limit the sensitivity and therefore the 
dynamic range.
Tyrosine Phosphorylation Quantification in EGFR signaling
Previous studies have described the temporal dynamics of individual tyrosine 
phosphorylation sites following EGFR activation8. Although these studies have highlighted 
many novel phosphorylation sites in the network and have led to hypotheses regarding the 
function of selected sites, they have been inherently limited by quantification relative to a 
selected time point. As such, it has been difficult to quantify differences in phosphorylation 
levels across different sites on the receptor, or to determine whether different ligands led to 
different phosphorylation stoichiometries. To address this deficiency and gain insight into 
the temporal phosphorylation profiles of multiple sites in the network, we used MARQUIS 
to quantify absolute levels of tyrosine phosphorylation on EGFR and proximal adaptor 
proteins, at multiple time points following EGF stimulation. Although EGFR pY1173 is 
often cited as a dominant autophosphorylation site for the receptor9, and is often used as a 
measure of EGFR activation for immunoblotting studies10,11, MARQUIS data 
unequivocally demonstrates that phosphorylation of 1148 occurs approximately 4–5 fold 
greater than pY1173, pY1068, or pY1045, all of which occur at similar levels (Fig. 4a), a 
comparison that would be missed by typical MS-based relative quantitation6 or 
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immunoblotting techniques. Further downstream in the network, it is also possible to detect 
higher levels of phosphorylation on Erk2 pY187 as compared to Erk1 pY204 (Fig. 4b), an 
observation that aligns with higher ERK2 expression in other systems12.
Absolute quantification enables the tracking of individual phosphorylation sites, even when 
multiple sites are contained within the same tryptic peptide. For instance, the peptide 
containing Y1148 also contains S1142, a serine residue that has previously been found to be 
phosphorylated in these cells13. To identify whether pS1142 co-occurs with pY1148 on the 
same EGFR protein, we used MARQUIS for absolute quantification of the singly 
phosphorylated pY1148 peptide and the doubly phosphorylated pS1142/pY1148 peptide. By 
quantifying the singly and doubly phosphorylated isoforms of the peptide, we could more 
accurately account for the total amount of phosphorylation on Y1148 (Fig. 4c). This analysis 
led to the intriguing finding that pS1142/pY1148 is present in unstimulated cells at 
approximately the same level as the singly phosphorylated pY1148, but upon stimulation 
gradually decreases over time. In comparison, the singly phosphorylated pY1148 increases 
strongly following EGF stimulation. With absolute quantification, it is clear that the increase 
in phosphorylation of the singly phosphorylated pY1148 is much greater than the decrease 
in the doubly phosphorylated pS1142/pY1148 peptide. Therefore, the increase in singly 
phosphorylated pY1148 is likely due to phosphorylation of EGFR in the absence of pS1142, 
rather than de-phosphorylation of the pS1142/pY1148 species. It remains to be determined 
whether pS1142 inhibits phosphorylation of Y1148, but our data would be consistent with 
this hypothesis.
Additional insights into phosphorylation dynamics are available when multiple tyrosine 
phosphorylation events occur on a given tryptic peptide. For instance, Y1045 and Y1068 fall 
within the same tryptic fragment, and therefore yield four possible phosphorylation isoforms 
for the peptide (Y1045/Y1068, pY1045/Y1068, Y1045/pY1068, and pY1045/pY1068), 
three of which were monitored by MARQUIS-based absolute quantification (Fig. 4d). 
Although all three isoforms are present at similar, low levels in unstimulated MCF10A cells, 
following stimulation Y1045/pY1068 and doubly phosphorylated pY1045/pY1068 both rise 
rapidly in the first minute. The pY1045/Y1068 peptide increases gradually in the first 
minute, potentially indicating that this site is being converted to the pY1045/pY1068 form 
through rapid phosphorylation of Y1068. Interestingly, over the next several time points the 
singly phosphorylated Y1045/pY1068 isoform begins to decrease, while the pY1045/Y1068 
and pY1045/pY1068 isoforms both increase strongly, indicating phosphorylation of Y1045 
that is converting Y1045/pY1068 into the doubly phosphorylated form, which is the most 
abundant of the three isoforms in this early time period. Finally, by five minutes all three of 
the phospho-isoforms begin to decrease at similar rates, potentially indicating the activity of 
a common phosphatase. The quantitative interplay between these isoforms has not been 
previously documented due to a lack of absolute quantification of phosphorylation level on 
each of these sites under different stimulation conditions.
MARQUIS-based absolute quantification was also used to quantify EGFR phosphorylation 
dynamics in response to different EGFR ligands. It has previously been documented that 
stimulation with Epidermal Growth Factor (EGF), Transforming Growth Factor α (TGFα), 
or Amphgiregulin (AREG) leads to different downstream biological effects14–16, potentially 
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due to qualitatively or quantitatively different signaling networks. To uncover the 
mechanism by which these different ligands activate different phenotypes, we quantified the 
temporal dynamics of phosphorylation levels on multiple sites on the receptor and several 
downstream adaptor or effector proteins in response to different concentrations of each 
ligand (Supplemental Table 4). As can be seen in Figures 5a–c, each ligand stimulates a 
rapid increase in receptor phosphorylation, albeit to different levels, with the Y1148 site 
consistently phosphorylated to a greater extent compared to the other three phosphorylation 
sites on the C-terminal tail of the receptor. Given that each ligand has different binding 
affinities, the difference in the level of phosphorylation on the receptor may not be 
surprising. Intriguingly, despite the quantitative difference in the level of phosphorylation 
due to each ligand (Fig. 5d), the pattern of phosphorylation on the receptor is effectively 
invariant with regard to ligand identity, with pY1148>pY1068>pY1173>pY1045; this 
similarity in receptor pattern can best be visualized by normalizing all sites for a given 
ligand to the total amount of phosphorylation on the receptor (Fig. 5e). The consistent 
pattern of receptor phosphorylation at this ligand dose raises the intriguing possibility that 
biological response to different EGFR ligands may be encoded in the absolute level of 
phosphorylation on each site, rather than through the phosphorylation of different sites on 
the receptor (e.g. quantitative vs. qualitative control of RTK phosphorylation signaling 
networks). Interestingly, quantitative control at the receptor level results in altered 
phosphorylation patterns even on proximal adaptor proteins such as Gab1 (Supplementary 
Table 4); the mechanism underlying these pattern changes is currently unknown, but it is 
likely that changes in the amount of phosphorylation at the receptor may affect recruitment 
of other enzymes (kinases/phosphatases) or stearic competition for binding to the receptor, 
thus leading to different protein complex assembly.
Quantification of EGFR signaling in Glioblastoma Xenografts—To assess the 
applicability of the MARQUIS method to the complex biological background represented by 
tissue samples, we chose a set of patient-derived xenografts (PDX) that vary in their EGFR 
expression and mutation profiles: GBM12 expresses a point mutation the extracellular 
domain of EGFR; GBM6 and GBM39 express the constitutively active truncation mutant 
EGFR vIII; and GBM15 is EGFR wild-type amplified. Before searching for the endogenous 
signals, we confirmed that we could still build a large-dynamic-range standard curve in the 
more complex tumor background (Supplementary Figure 7 and 8). In the worst cases, we 
were still able to cover at least two orders of magnitude, convincing us that we could 
adequately measure endogenous levels.
With MARQUIS in PRM mode, we compared the absolute levels of phosphorylation for 
each EGFR phosphorylation site both within each PDX tumor model and across the various 
tumor models (Figure 6a and Supplementary Table 6, (validated spectra for each 
quantification scan are included in Supplementary Figure 9a–d)). For these PDX tumors, 
GBM6 (EGFRvIII) had the lowest level of EGFR phosphorylation, consistent with previous 
literature describing EGFRvIII as a weakly constitutively active kinase. Interestingly, 
GBM39 also expresses EGFRvIII, but is much more highly phosphorylated on the receptor. 
By comparison, GBM12 (EGFR point mutant) demonstrated an intermediate level of 
receptor phosphorylation and GBM15, the wild-type EGFR amplified PDX tumor, had the 
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highest level of phosphorylation. Large variation was observed in the different GBM15 
tumor samples, potentially due to biological fluctuations between replicate tumors. 
Intriguingly, the pattern of EGFR phosphorylation was invariant when comparing the wild-
type EGFR (GBM15) to the point mutant (GBM12) or the EGFRvIII mutation (GBM6 and 
GBM39), providing a separate example of quantitative vs. qualitative regulation of receptor 
phosphorylation. For proximal adaptor proteins, little significant difference was observed in 
Gab1 Y406 phosphorylation (Figure 6b), but Shc pY317 levels (Fig. 6c) were elevated for 
GBM12 and GBM 39 relative to GBM15 and GBM6. Downstream of SHC and GAB1, 
ERK2 was most highly phosphorylated in GBM12 and GBM15, while ERK1 
phosphorylation levels were similar across all four GBM PDX tumors (Figure 6d). It is 
worth noting that this data is in general agreement with our previous analysis of the 
signaling networks in these GBM PDX tumor lines17, except that MARQUIS provides 
absolute levels of quantification for the specific phosphorylation sites in each sample.
As an additional application, MARQUIS enables the absolute quantification of the effects of 
therapeutic treatment on tumor samples. In many cases, it is not known whether resistance 
arises due to failure to inhibit the target or due to compensatory signaling mechanisms. To 
quantify the effect of EGFR tyrosine kinase inhibitor treatment in vivo, GBM12 was treated 
with a panel of kinase inhibitors (Erlotinib, Dacomitinib, or NT-113), to compare the 
efficacy of a classic Type 1 inhibitor (Erlotinib) with the latest generation of covalent HER-
family inhibitors (Dacomitinib and NT-113). Following tumor homogenization, the 
MARQUIS workflow was employed in PRM mode with the same heavy-labeled standard 
peptides and full-scan data collection LC-MS (validated spectra for each quantification scan 
are included in Supplementary Figure 8). The results of these analyses are presented in 
Figure 7 and data is in Supplementary Table 7. EGFR phosphorylation (Fig. 7a) in the 
placebo treated tumors continues to resemble the patterns observed in the MCF10A cells 
treated with EGF. Following treatment with each of the inhibitors, EGFR phosphorylation 
on each site decreased significantly, by >90% on pY1068, pY1148, and pY1173, indicating 
effective inhibition of the target for each kinase inhibitor. Phosphorylation on the proximal 
adaptor proteins Gab1 pY285, Gab1 pY659 (Fig 7b), and Shc pY317 (Fig. 7c) also 
decreased in response to each of the inhibitors, which corresponded to a decrease in Erk1 
and Erk2 phosphorylation (Figure 7d). None of the inhibitors had a significant impact on Src 
Y418 phosphorylation, but NT-113 decreased Shp2 phosphorylation on Y62 to a greater 
extent (~44% decrease) compared to dacominitib (~22%) and erlotinib (~10%).
Discussion
MARQUIS is a novel multi-point internal standard calibration method that enables absolute 
quantification of site-specific PTM levels or protein expression. The method provides 
accurate quantification over a broad range of concentrations allowing simultaneous analysis 
of stimulation conditions that lead to large changes in expression or modification levels. 
With MARQUIS, absolute quantitation data can be collected for many PTM sites of interest 
in the network in a single analysis, using either MRM or PRM-based targeted mass 
spectrometry. This data can then be used for intra- and inter-sample site-specific 
comparisons.
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It is well known that isobaric labeling strategies such as iTRAQ or TMT suffer from ratio 
compression in complex mixture analysis due to the inclusion of contaminating peptides 
during the isolation of the precursor peptide for fragmentation. Importantly, the MARQUIS 
method is novel in the inclusion of a standard curve within the biological sample, enabling 
the estimation of ratio compression at the same elution time as the endogenous peptides, and 
at a proximal mass-to-charge ratio. Thus, the MARQUIS method not only correctly 
estimates iTRAQ ratio compression, but also enables compensation for that compression, a 
feature that is inherently lacking in most other absolute or relative quantification methods.
It is also worth noting that the MARQUIS method enables accurate absolute quantification 
even for complex sample processing protocols prior to mass spectrometric analysis. Because 
synthetic phosphorylated peptides whose sequence matches exactly to the endogenous 
peptide are added during the cell lysis procedure, the MARQUIS method accounts for losses 
throughout post-digestion sample processing, including potentially inefficient 
immunoprecipitation of selected peptides or sub-optimal enrichment of phosphophorylated 
peptides.
MARQUIS was designed for MRM-based analysis on a triple quadrupole, but the method is 
equally applicable to targeted full-scan targeted tandem mass spectrometry (PRM). Overall, 
the two methods performed very well in terms of technical reproducibility with a CV 
threshold of 0.15 able to capture the majority of measurements with both techniques. Both 
instrument platforms offer selective advantages. For instance, the PRM method offers the 
ability to determine contamination by way of the complete MS/MS data at high resolution 
that is not available in an MRM experiment. On the other hand, when using MRM, the 
precursor (Q1) isolation window can be tightened to a greater extent compared to the PRM 
method, thereby improving signal-to-noise by reducing contributions from spurious co-
eluting ions. Although a Q1 isolation width of 0.7m/z was typically used for the data 
acquired in this study, sufficient signal for quantification can be attained for many peptides 
by using a window as small as 0.1m/z. Such a narrow window would be deleterious to the 
PRM method as the drop in ion flux may eliminate signal for most low and medium 
intensity fragments. The MRM approach is inherently more flexible, as the fragmentation 
energy and time spent per MRM transition can be altered for selected transitions to improve 
the sensitivity. However, increasing the dwell time is only feasible for a small number of 
transitions; otherwise the increase in cycle time becomes too great.
Recent structural insights into the cooperativity of ligand binding and EGFR dimerization 
suggest that differential ligand affinities for the extracellular portion of the receptor 
influence the occupancy and the receptor conformation and potentially signaling and 
trafficking18. A previous mass spectrometry-based study of receptor phosphorylation 
observed site-specific quantitative differences in receptor phosphorylation in response to 
varied doses of TGFα and EGF; stoichiometry was estimated by measuring the ratio of 
signal intensities between phosphorylated and non-phosphorylated versions of tyrosine 
containing tryptic fragments19. Such comparisons are limited due to the differential 
ionization potential between these species. Here we have shown large differences not only 
between various ligand stimulation conditions for a single site, but also between different 
EGFR sites not present on the same tryptic peptide.
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The MARQUIS method enables quantification of EGFR phosphorylation stoichiometry, 
information necessary to decipher how extracellular ligand concentration information is 
transmitted across the cellular membrane. Unique sets of SH2- and PTB-containing proteins 
bind to each receptor phosphorylation site20,21, suggesting the ability to activate distinct 
pathways by phosphorylating different sites. Alternately, differential pathway activation 
could be controlled by altering the level of phosphorylation. While this option might suggest 
that downstream pathways will be linearly proportional to receptor phosphorylation levels, 
different pathways feature amplification gains, and thus one pathway might be saturated by 
a relatively small signal on the receptor, as has been detected for the ERK MAPK pathway, 
while other pathways may be more analog in nature. Here, through absolute quantification 
of specific phosphorylation sites on the receptor, we determined that the EGFR 
phosphorylation response to stimulation with a relatively high concentration of different 
EGFR ligands is quantitatively regulated. Although phosphorylation levels are ligand 
specific, the ratio between different receptor sites is constant across different EGFR ligands. 
Thus, different biological responses may be regulated by the analog vs. digital nature of the 
different downstream pathways, in a manner analogous to the interleukin receptor system we 
have recently investigated22. Additional studies are needed to confirm the effects of 
quantitative regulation of receptor phosphorylation on downstream pathways, as well as to 
determine the cellular conditions that might lead to altered phosphorylation patterns on the 
receptor: is this a mechanism by which the cell differentiates normal vs. pathological 
signaling?
Finally, we have demonstrated the applicability of the MARQUIS method to generate 
absolute phosphorylation quantification data in tumor tissues. Because MARQUIS provides 
absolute quantification in a multiplexed analysis, it enables quantification across different 
MS analyses, now providing the potential to generate absolute quantification of hundreds of 
tumor samples in a relatively small number of MS analyses. Furthermore, we have used 
MARQUIS to quantify the effects of therapeutic inhibition on these same tumor tissues. 
These data demonstrate the ability of MARQUIS to not only quantify the effect of different 
TKIs on target phosphorylation levels, but also to quantify the effect of the inhibitor on 
proximal adaptor proteins, downstream effectors, and off-target kinases.
Absolute quantification of protein expression and PTM levels will be required to provide 
insight into regulation of many biological systems. The MARQUIS method enables facile 
acquisition of absolute quantification data across multiple biological conditions 
simultaneously, with large dynamic range, and with internal standard curves to improve the 
accuracy of the measurements. This method is broadly applicable to multiple mass 
spectrometry platforms and to different biological systems.
Methods
Sample Preparation
MCF10A cells (originally provided by the Brugge lab at Harvard Medical School) were 
serum-starved 24 hours prior to stimulation with 20nM EGF (Peprotech) for 0.5, 1, 2, 3, 5, 
10 or 30 minutes. Media was aspirated and cells were lysed with 2ml of cold 8M urea with 
1mM activated sodium orthovanadate. Lysate was frozen at −80 until further processing. 
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Protein yield was quantified by BCA assay (Pierce) in order to ensure equal loading. 
Standard peptides were added to samples as in Supplementary Table 1. Samples were 
reduced with 40µl 10mM DTT in ammonium acetate pH 8.9 for 1 hour at 56 C. Samples 
were alkylated with 55mM iodoacetamide in ammonium acetate pH 8.9 for 1 hour at room 
temperature. 8mL ammonium acetate and 40µg of sequencing grade trypsin was added prior 
to 16 hours incubation at room temperature. Lysates were acidified with 1 mL glacial acetic 
acid and protein was purified with Waters Sep-Pak columns. Samples were lyophilized and 
subsequently labeled with iTRAQ 8plex (AbSciex) per manufacturer’s directions.
Standard Peptide Preparation and Quality Assurance
Standard peptides were synthesized at the Koch Institute Biopolymers facility and amino 
acid analysis was performed to measure concentration by AAA Service Laboratories 
(Damascus, OR). Synthetic peptides were analyzed by LC MS/MS to confirm sequence and 
purity.
Multiple Reaction Monitoring (MRM)
Immunoprecipitation—70ul protein G agarose beads (calbiochem IP08) were rinsed in 
400ul IP Buffer (100mM tris, 0.3% NP-40, pH 7.4) prior to an 8 hour incubation with a 
cocktail of three phosphotyrosine-specific antibodies (12µg 4G10 (Millipore),12ug PT66 
(Sigma), and 12ugPY100 (CST)) in 200ml IP Buffer. Antibody cocktail was removed and 
beads were rinsed with 400ul of IP Buffer. Labeled samples were resuspended in 150ul 
iTRAQ IP Buffer (100mM Tris, 1% NP-40, pH 7.4) + 300ul milliQ water and pH was 
adjusted to 7.4 (with 0.5M Tris HCl pH 8.5) prior to addition to prepared beads and 16 hour 
incubation. Supernatant was removed and beads were rinsed 3 times with 400ul Rinse 
Buffer (100mM Tris HCl, pH 7.4). Peptides were eluted in 70ul of Elution Buffer (100mM 
glycine, pH 2) for 30 minutes at room temperature.
Immobilized Metal Affinity Chromatography (IMAC) Purification—A fused silica 
capillary (FSC) column (200µm ID×10cm length) was packed with POROS 20MC beads 
(Applied Biosystems cat.no. 1-5429-06). Column was rinsed with 100 mM EDTA pH 8.9 in 
ultrapure water to remove residual iron and then rinsed with ultrapure water to remove 
EDTA before fresh iron was deposited by rinsing with 100 mM FeCl3 in ultrapure water. 
Excess iron was removed with 0.1% acetic acid prior to loading the IP elution. The column 
was washed with 25% MeCN, 1% HOAc, 100 mM NaCl in ultrapure water to remove non-
specifically bound peptides and then rinsed with 0.1% HOAc. Peptides were eluted with 
250mM NaH2PO4 in ultrapure water and collected on a pre-column (100µm ID × 10cm 
packed with 10µm C18 beads (YMC gel, ODS-A, 12nm, S-10 µm, AA12S11)). This pre-
column was rinsed with 0.2M acetic acid prior to LCMS analysis.
Liquid Chromatography Mass Spectrometry—The pre-column was connected in-
line with an analytical column (50µm ID × 10cm packed with 5µm beads (YMC gel, ODS-
AQ, 12nm, S-5 µm, AQ12S05)) with integrated electrospray emitter tip [Martin 2000]. A 
140 minute gradient from aqueous (0.2M acetic acid) and organic phase (0.2M HOAc, 70% 
MeCN) was used to separate peptides with a flow rate of 200 nL/min and a flow split > 99% 
and a spray voltage of 1800 V. Isolation widths of 0.7 were used for both Q1 and Q3 and 
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collected for 0.05 seconds. A width of 0.01m/z was collected around each transition for 
quantification. Collision energies were determined per sequence with Thermo Pinpoint 
software.
Absolute Quantitation—Analyses were performed on a Thermo TSQ Quantum in MRM 
mode. Endogenous and heavy-labeled versions of each peptide of interest were tracked 
throughout the experiment with two sequence specific transitions (precursor/prominent b or 
y ion) and eight iTRAQ transitions (precursor/label peak). Elution time was determined 
based on co-elution of iTRAQ transitions with sequence specific transitions for both 
standard and endogenous peptides of the MARQIS pair. Area Under the Curve (AUC) was 
collected for each transition. Data were corrected by iTRAQ isotope purity and synthetic 
peptide loading control. A calibration curve was created for each peptide to relate the AUC 
of the iTRAQ transition to the amount of standard included. MATLAB function lscov was 
used with the intensity of the signal also serving to appropriately scale the variance. This 
calibration curve was then used to calculate the amount of peptide present in each of the 
endogenous conditions based on the corresponding iTRAQ transition AUC.
Parallel Reaction Monitoring (PRM)
Immunoprecipitation—20 µl protein G agarose beads (Calbiochem, IP04-1.5ML) were 
pre-incubated with 20µl of PT66 and 20µl of pY100, prior to adding sample (reconstituted in 
70µl HEPES buffer adjusted with 5M NaOH). After overnight incubation, beads were rinsed 
and peptides were eluted with 20µL of 0.1% TFA, 10% MeCN, 250ng/µL HeLa Digest 
(phospho depleted).
NTA Enrichment—Elution incubated with Fe(III)-NTA magnetic beads for 15 minutes, 
rinsed and eluted with 10µL of NH4OH (1:30), 5mM EDTA, 5% MeCN, 1ng/µl HeLa 
digest. Elution was transferred to an autosampler vial and pH was adjusted with 5µl of 10% 
TFA.
Liquid Chromatography Mass Spectrometry—LC-MS was performed using a 25cm, 
75µm ID, EASY-Spray column (ThermoFisher Scientific, ES802) with a 120 minute 
gradient and a flow rate of 300µl/min and a spray voltage of 1800 V. Targeted MS2 scans 
were collected with a maximum ion injection time of 2 seconds and an AGC target of 3e6 
with an MS1 isolation width of 1 m/z and fragmented with a collision energy of 35.0.
Absolute Quantitation (PRM method)—Analyses were performed on a Thermo Q-
Exactive. Endogenous and heavy-labeled versions of each peptide were targeted for MS2 
analysis during their expected elution times. In the MS1 scan, the total amount of 
endogenous peptide was calculated based on the fraction of MS1 integrated intensity when 
compared to the standard peptide. This amount was then apportioned across the contributing 
samples based on relative iTRAQ intensity. A single point measurement where the MS2 
scan used to determine the iTRAQ intensity ratios was chosen based on maximal MS1 
intensity to assure maximal signal to noise ratio.
Curran et al. Page 13














All studies were reviewed and approved by the Mayo Institutional Animal Care and Use 
Committee. Subcutaneous xenografts for GBM 6, 12, 15, and 39 were established by 
injecting the flank of athymic nude mice with 1 × 106 cells suspended in Matrigel/PBS. 
Tumors were harvested and flash frozen in liquid nitrogen once they reached >1500 mm3 in 
size. For the GBM 12 pharmacodynamic study, eight mice had flank tumors implanted and 
randomized into four treatment arms once the tumor reached at least 200 mm3 in size: 1) 
Placebo 2) erlotinib 100 mg/kg 3) dacomitinib 10 mg/kg 4) NT-113 15 mg/kg. A single dose 
was given to each mouse and the tumor was harvested at six hours post-treatment and flash 
frozen in liquid nitrogen.
500 µg of protein (as determined by BCA assay) from each tumor sample was processed as 
per the PRM LC-MS protocol following IP and IMAC enrichment as previously described. 
Analyses were performed on a Thermo Q Exactive instrument fed by a Thermo Easy 
nLC1000 UPLC precolumn (Thermo 164705) and a self-pack PicoFrit analytical column 
(New Objective PF360-50-10-N-5) packed with 50 cm of 3um beads (ODS-AQ 12nm 
S-3um from YMC America AQ12S03). Samples were analyzed on a 60 minute gradient 
with a 200 nL/min flow rate; aqueous phase: 0.1% Formic Acid in HPLC-grade water, 
organic phase: 0.1% Formic Acid, 80% Acetonitrile in HPLC-grade water. A spray voltage 
of 2000 V was used.
To ensure that the standard peptides did not contaminate the endogenous iTRAQ signals, 
each sample was run twice. Quantitative iTRAQ data for the endogenous peptides was 
collected from Sample A, as Sample A did not contain standard peptides that may 
potentially contaminate endogenous iTRAQ signal. MS/MS scans of endogenous peptides 
were collected with a 250 ms fill time, an AGC target value of 5e5 and an isolation window 
of 2 m/z. Quantitative iTRAQ data for the synthetic heavy-labeled standard peptides as well 
as the ratio between standard and endogenous precursor peaks were collected from Sample 
B. MS/MS scans were optimized to collected the largest dynamic range possible by 
maximizing the fill time (3s) and the AGC target (5e6).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Variability of Signal Intensity from Technical Replicates
The signal intensity vs. amount of peptide is plotted for three representative peptides across 
five technical replicate analyses.
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Figure 2. MARQUIS Method for Absolute Quantification
Synthetic isotope-labeled phosphorylated peptides (represented by the square box) are added 
during cell lysis. Following sample processing and digestion, all peptides, synthetic and 
endogenous (represented by the circle), are iTRAQ labeled. For this particular application of 
the method, tyrosine phosphorylated peptides are enriched by peptide immunoprecipitation 
followed by immobilized metal affinity chromatography (IMAC) and analyzed by LC-
MS/MS. Heavy-labeled standards provide an internal calibration curve, enabling absolute 
quantification of endogenous peptides.
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Figure 3. Quality Comparison of MARQUIS on the MRM vs. PRM Platform
Observed vs. Expected total iTRAQ signal contribution for MRM and PRM methods for 
two sites: EGFR pY1173 (a) and Shc pY317 (b). c) Coefficient of Variation vs. Amount for 
MRM and PRM methods. d) Fraction of measurements that meet Coefficient of Variation 
(CV) thresholds for both techniques. Data represents mean and standard deviation across 
five technical replicates.
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Figure 4. Stoichiometric Comparison of Site-Specific Phosphorylation
Data for a collection of EGFR and network phosphorylation sites was gathered using 
MARQIS with Multiple Reaction Monitoring (MRM) on a triple quadrupole instrument. a) 
EGFR. b) ERK1/2. c) EGFR pY1148, pS1142/pY1148. d) EGFR pY1045, pY1068, and 
pY1045/pY1068. Data represent mean and standard deviation across three biological 
replicates.
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Figure 5. Ligand Comparison
MRM-based absolute quantitation for EGFR phosphorylation sites treated with EGF (a), 
TGFα (b), and AREG (c). Comparison of site-specific phosphorylation between ligands 
following five minutes of ligand stimulation for two biological replicates; raw (d) and 
normalized (e). Data represent mean and range across two biological replicates.
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Figure 6. Quantification of Phosphorylation Across Four Glioblastoma Patient-Derived 
Xenograft Tumor Types
Absolute amounts of phosphorylation were quantified for each patient-derived xenograft 
mouse model of glioblastoma. Each tumor model was analyzed in biological duplicate. 
EGFR (a). Gab1 (b). Shc (c). Erk1/2 (d). Data represent mean and range across two 
biological replicates.
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Figure 7. Quantification of Phosphorylation in a Glioblastoma Patient-Derived Xenograft 
Treated with a Panel of EGFR Kinase Inhibitors
Absolute amounts of phosphorylation were quantified in the GBM12 patient-derived 
xenograft tumors treated with placebo or one of three EGFR kinase inhibitors: Erlotinib (100 
mg/kg), Dacomitinib (10 mg/kg), or NT-113 (15 mg/kg). Each treatment condition was 
analyzed in biological duplicate. EGFR (a). Gab1 (b). Shc (c). Erk1/2 (d). Data represent 
mean and range across two biological replicates.
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